NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis $76.99 0.00 (0.00%) As of 08/27/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Forte Biosciences Stock (NASDAQ:FBRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Forte Biosciences alerts:Sign Up Key Stats Today's Range$76.99▼$76.9950-Day Range$43.20▼$76.9952-Week Range$10.11▼$77.20VolumeN/AAverage Volume1.86 million shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/APrice Target$71.67Consensus RatingHold Company Overview Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies for inflammatory and immune-mediated skin diseases. The company’s approach involves using naturally occurring microorganisms and their biological effects to help restore healthy skin function and address disease-related inflammation. Forte’s lead product candidate has been FB-401, a topical live biotherapeutic product based on Roseomonas mucosa, a naturally occurring bacterium found on human skin. The program was developed primarily for the potential treatment of atopic dermatitis, a chronic inflammatory skin condition. Forte has evaluated FB-401 in clinical studies and has used the results to guide its research and development strategy. Founded in 2016, Forte Biosciences is headquartered in Dallas, Texas. The company’s activities have primarily centered on developing therapies for dermatological and immune-related conditions, with its research directed toward patients in markets where these diseases represent significant unmet medical needs.AI Generated. May Contain Errors. Read More Forte Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreFBRX MarketRank™: Forte Biosciences scored higher than 19% of companies evaluated by MarketBeat, and ranked 821st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingForte Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.Downside RiskForte Biosciences has a consensus price target of $71.67, representing about 6.9% downside from its current price of $76.99.Amount of Analyst CoverageForte Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Forte Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Forte Biosciences are expected to decrease in the coming year, from ($4.27) to ($4.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forte Biosciences is -16.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forte Biosciences is -16.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForte Biosciences has a P/B Ratio of 8.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Forte Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.04% of the float of Forte Biosciences has been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 1.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Forte Biosciences has recently decreased by 14.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldForte Biosciences does not currently pay a dividend.Dividend GrowthForte Biosciences does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for FBRX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Forte Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.40% of the stock of Forte Biosciences is held by insiders.Percentage Held by Institutions77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Forte Biosciences' insider trading history. Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FBRX Stock News HeadlinesForte Biosciences, Inc. (NASDAQ:FBRX) Receives Consensus Rating of "Hold" from BrokeragesSeptember 9, 2026 | americanbankingnews.comForte Biosciences Completed Take-Private Merger and DelistingAugust 29, 2026 | theglobeandmail.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 19 at 1:00 AM | Profits Run (Ad)Argenx Completes Acquisition of Forte BiosciencesAugust 27, 2026 | finance.yahoo.comHedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte BiosciencesAugust 11, 2026 | insidermonkey.comForte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRXAugust 11, 2026 | businesswire.comFBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its ShareholdersAugust 8, 2026 | businesswire.comThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTXAugust 6, 2026 | globenewswire.comSee More Headlines FBRX Stock Analysis - Frequently Asked Questions How have FBRX shares performed this year? Forte Biosciences' stock was trading at $27.27 at the beginning of 2026. Since then, FBRX shares have increased by 182.3% and is now trading at $76.99. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) issued its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.97) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.03. When did Forte Biosciences IPO? Forte Biosciences (FBRX) raised $94 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 8,500,000 shares at $10.00-$12.00 per share. Who are Forte Biosciences' major shareholders? Top institutional shareholders of Forte Biosciences include AWM Investment Company Inc. (1.60%), Wellington Management Group LLP (0.32%), Bank of New York Mellon Corp (0.29%) and Squarepoint Ops LLC (0.06%). Insiders that own company stock include Paul A Wagner and Antony A Riley. View institutional ownership trends. How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Forte Biosciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), PayPal (PYPL), Qualcomm (QCOM), Avino Silver & Gold Mines (ASM), Meta Platforms (META) and Zoom Communications (ZM). Company Calendar Last Earnings8/12/2026Today9/19/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 FBRX's financial health is in the Green zone, according to TradeSmith. FBRX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FBRX CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees5Year Founded2001Price Target and Rating Average Price Target for Forte Biosciences$71.67 High Price Target$77.00 Low Price Target$61.00 Potential Upside/Downside-6.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($4.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-94.82% Return on Assets-77.68% Debt Debt-to-Equity RatioN/A Current Ratio10.01 Quick Ratio10.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.66 per share Price / Book8.89Miscellaneous Outstanding Shares21,229,000Free Float20,295,000Market Cap$1.63 billion OptionableOptionable Beta2.62 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:FBRX) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
